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Abstract
Background: Rapid eye movement (REM) sleep behavior disorder (RBD) is a common parasomnia in Parkinson’s
disease (PD) patients. The current International Classification of Sleep Disorders (ICSD-II) requires a clinical interview
combined with video polysomnography (video-PSG) to diagnose. The latter is time consuming and expensive and
not always feasible in clinical practice. Here we studied the use of actigraphy as a diagnostic tool for RBD in PD
patients.
Methods: We studied 45 consecutive PD patients (66.7% men) with and without complaints of RBD. All patients
underwent one night of video-PSG and eight consecutive nights of actigraphy. Based on previous studies, the main
outcome measure was the total number of bouts classified as “wake”, compared between patients with (PD + RBD)
and without RBD (PD- RBD).
Results: 23 (51.1%) patients had RBD according to the ICSD-II criteria. The total number of wake bouts was significantly
higher in RBD patients (PD + RBD 73.2 ± 40.2 vs. PD-RBD 48.4 ± 23.3, p = .016). A cut off of 95 wake bouts per night
resulted in a specificity of 95.5%, a sensitivity of 20.1% and a positive predictive value of 85.7%. Seven patients
were suspected of RBD based on the interview alone, but not confirmed on PSG; six of whom scored below 95
wake bouts per night on actigraphy.
Conclusion: PD patients with RBD showed a significantly higher number of bouts scored as “wake” using actigraphy,
compared to patients without RBD. In clinical practice, actigraphy has a high specificity, but low sensitivity in the
diagnosis of RBD. The combination of actigraphy and previously reported RBD questionnaires may be a promising
method to diagnose RBD in patients with PD.
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Background
Rapid eye movement (REM) sleep behavior disorder
(RBD) is a parasomnia that occurs frequently in patients
with Parkinson’s disease (PD), with an estimated preva-
lence of 30-60% [1-3]. RBD is characterized by the en-
actment of dreams as a result of the loss of physiological
atonia during REM sleep. Behaviors displayed include
hitting, kicking, shouting but also laughing. The associated
dreams are often violent or frightening in origin, and
sometimes patients harm themselves or their bed partners
with their movements [1]. Remarkably, the RBD-associated
movements of PD patients are usually much faster, stron-
ger and smoother than during the day, suggesting
that the movements “bypass” the affected extrapyramidal
systems [4].
To make a diagnosis of RBD, the current 2nd edition
of the International Classification of Sleep Disorders
(ICSD-II) requires the combination of clinical features
(either by history or on nocturnal video recordings) and
the presence of REM sleep without atonia as an elec-
tromyographic (EMG) finding during sleep recordings
(Table 1) [5]. The gold standard for the diagnosis of
RBD therefore entails a clinical interview, preferably by
a sleep medicine specialist, together with at least one
night of polysomnography with audiovisual recordings
(video-PSG). However, referring every PD patient with
complaints of nocturnal restlessness to a sleep medicine
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center is time-consuming, expensive and may not always
be feasible in clinical practice. As a result, many movement
disorder specialists base their diagnosis of RBD solely on
the description of the typical behaviors by the bed partner
of the patient. Studies show that this practice results in fre-
quent misdiagnoses [6] and, consequently, overtreatment.
Mimicking disorders such as obstructive sleep apnea, con-
fusional arousals and nocturnal hallucinations should be
excluded [7], especially because some of these may worsen
with clonazepam, the first-line treatment of RBD. There-
fore, there is a need for less expensive, easy to use methods
to diagnose RBD.
The REM sleep behavior disorder screening question-
naire (RBDSQ) was developed as an easy to use screen-
ing method [8,9]. The scale was created in German and
English and more recently a Japanese version has been
validated [10]. Although the questionnaire shows good
internal consistency and a high sensitivity (96%) com-
pared to the clinical interview, it has a low specificity
(56%) [8]. The REM sleep behavior disorder questionnaire
Hong Kong (RBDQ-HK) has been developed, tested and
validated in Chinese patients based on the ICSD-II criteria
[11]. It was validated in a group of PSG-confirmed RBD
patients and controls. The overall RBDQ-HK score was
significantly higher in the RBD group. ROC analysis
showed that a cut off score of 18/19 had moderate sensi-
tivity and specificity [11]. More recently Frauscher et al.
published a validation study of the Innsbruck REM sleep
behavior disorders inventory [12]. The scale had a sensitiv-
ity of 91.4% and a specificity of 85.7% for both idiopathic
and PD related RBD (AUC, 0.886). Interestingly, the
scores of patients sleeping alone were comparable with
patients with a bed partner.
Actigraphy has been suggested as another possible
diagnostic tool for RBD. Actigraphy may be a useful in-
strument to obtain general measures such as total sleep
time, sleep efficiency and wake after sleep onset [13,14].
Compared to questionnaires, actigraphy should give a
more objective representation of actual motor activity
during the night. In addition, actigraphy is much less ex-
pensive and cumbersome compared to video-PSG and
could be used in a home setting for several days, which
may compensate for night-to-night fluctuations in the
presence or severity of RBD symptoms. As such the use
of actigraphy in the diagnosis of RBD seems attractive
and the first results on its use are indeed promising.
Naismith et al. found that PD patients with RBD had a
higher number of bouts scored as “wake” by actigraphy,
compared to patients without RBD, based on question-
naires [15]. In the current study, we sought to confirm
these findings in a larger group of well-defined PD patients.
We compared actigraphy outcomes in PD patients with
and without RBD, based on the gold standard of a clinical
interview in combination with video-PSG. Furthermore we
searched for an optimal cut-off point to actually implement
the use of actigraphy in clinical practice.
Methods
Design and study population
All patients were recruited from Sleep Medicine Centre
Kempenhaeghe, a tertiary clinic for patients with sleep
disorders in the Netherlands. At Kempenhaeghe, PD
patients with sleep complaints are seen in a dedicated pro-
gram, including an extensive clinical consultation followed
by attended video-PSG that night. Referral reasons could
be diverse e.g. insomnia, restless legs syndrome, sleep
apnea, and thus did not only pertain to RBD. We included
all consecutive idiopathic PD patients referred to the clinic
as part of their regular care. All patients satisfied the UK
Brain bank criteria for PD and were assessed using their
usual medication. Data were collected as part of the regu-
lar medical care. The study was performed according
to the guidelines of the Medical Ethical Committee of
the Radboud University Nijmegen Medical Centre. All
patients gave informed consent to use these data for fur-
ther study.
Clinical characteristics
Demographic, clinical and disease characteristics were
recorded. Disease stage was rated using the Hoehn &
Yahr staging system [16]. The use of levodopa mono
therapy, dopamine agonist mono therapy and combination
Table 1 ICSD-II criteria for REM sleep behavior disorder
A Presence of REM sleep without atonia; the EMG finding of excessive amounts of sustained or intermittend elevation of sub-mental EMG
tone or excessive phasic submental or (upper or lower) limb EMG twitching.
B At least one of the following is present:
I. Sleep related injurious, or disruptive behaviors by history
II. Abnormal REM sleep behaviors documented during PSG monitoring
C Absence of EEG epileptiform activity during REM sleep unless RBD can be clearly distinguished from any concurrent REM sleep-related
seizure disorder.
D The sleep disturbance is not better explained by any other sleep disorder, medical or neurological disorders, mental disorders, medication
use, or substance abuse
EMG, electromyography, EEG, electroencephalography, PSG, polysomnography, RBD, REM sleep behavior disorder, REM, rapid eye movement.
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therapies was registered. Overall dopaminergic treatment
was quantified by calculating the Levodopa Equivalent
Dose (LED) in mg/day [17]. In addition, nocturnal dopa-
minergic treatment was estimated by the dopaminergic
dose taken before going to bed in LED (LED-night). The
use of anti-depressants -which can cause or aggravate
RBD- was actively asked for and listed.
RBD diagnosis
The diagnosis of RBD was made according to the ICSD-II
criteria. During the clinical interview, the presence of
movements and vocalizations during sleep was screened
for by a sleep specialist experienced with PD (ML and SO).
The interview was followed by one night of video-PSG.
Sleep was scored by laboratory technicians highly experi-
enced with scoring polysomnographic recordings in PD
patients, and checked by a sleep medicine specialist (SO).
The presence of REM sleep without atonia was determined
by quantifying the EMG-signal of the m. submentalis using
the “SinBar-group” criteria [18]. Tonic EMG activity was
scored in 30 seconds epochs and was considered patho-
logical if the amplitude was more than twice the back-
ground amplitude or exceeded 10 μV in more than 50% of
the epoch. Phasic EMG activity was scored in 3 seconds
mini-epochs and determined to be increased when it
contained a burst of EMG activity lasting between 0.1
and 5.0 seconds with an amplitude exceeding twice the
background activity. REM sleep without atonia was diag-
nosed when more than 18% of 3 second mini-epochs of
REM sleep contained increased tonic and/or phasic EMG
activity. Finally, the presence of abnormal REM sleep be-
haviors during PSG was determined using the synchro-
nized video recordings.
Actigraphy
Actigraphy was performed using the Actiwatch system
(Actiwatch AW4, Cambridge Neurotechnology Ltd,
Cambridgeshire, United Kingdom), a piezoresistive uni-
axial accelerometer. In agreement with previous studies,
the recording device was placed on the wrist of the least
affected site. Accelerometer signals were digitally sampled
at a rate of 32 Hz. The actigraphy device is small, comfort-
able to wear and according to the patients did not inter-
fere with their normal sleeping behavior. The first night of
measurement was done simultaneously with the clinical
PSG recording. Sleep and wake times were synchronized
with PSG “lights off” and “lights on”. After the first night
in the sleep center the actigraph was worn for seven con-
secutive nights at home. Actigraphy data were analyzed
using Sleep Analysis 7.23 software (Cambridge Neuro-
technology Ltd, Cambridgeshire, United Kingdom). Epoch
length was set on 0.25 min. Outcome measurements were
total sleep time, sleep efficiency, sleep latency, number and
length of wake bouts and total and mean activity scores.
Wake bouts during the sleep interval were defined as the
total number of continuous blocks in an interval where
the activity within the epoch was above the sleep thresh-
old and therefore scored as “wake”. The wake threshold
value (i.e. the number of activity counts used to define
wake) was set to medium sensitivity, i.e. 40.0 activity
counts per epoch.
Data analysis
Actigraphic measurements were compared between PD
patients with and without the diagnosis of RBD. Com-
parisons were tested using independent t-test and chi-
square test depending on the variable. As the Hoehn &
Yahr stage was not normally distributed, a Mann- Whitney
U test was used for this variable. Using Pearson’s cor-
relation coefficients, associations were analyzed between
the number of bouts classified as wake by actigraphy
and actual wake time during the PSG recording. Mul-
tiple regression analysis was used to correct for actual
wake time according to the PSG in the estimation of
the number of bouts classified as wake by actigraphy.
The diagnostic accuracy of the number of wake bouts
as a diagnostic tool for the presence of RBD, was
assessed using ROC analyses. Sensitivity, specificity and
positive predictive value were calculated. Missing values
were <5%, therefore all percentages are presented as valid
percentages. All data are shown as mean ± SD or N (%).
All results are based on two-tailed tests, with a significance
level set at p < .05.
Results
Study population
During the study period, 54 PD patients were included.
Nine patients were excluded from the analysis, one be-
cause of technical problems and eight because they had
less than 10 minutes of REM sleep during the PSG.
Twenty-three of the 45 remaining patients (51.1%) were
diagnosed with RBD according to the ICSD-II criteria.
Clinical and disease characteristics
In Table 2, clinical demographic as well as disease char-
acteristics of the study subjects are summarized. Patients
with RBD (PD + RBD) were older than those without
(PD-RBD). Disease severity was higher in patients with
RBD with longer disease duration and more advanced
H&Y disease stage (Table 2). PD + RBD patients used
higher doses of dopaminergic treatment. In the PD + RBD
group ten patients used levodopa only and thirteen pa-
tients used a combination of levodopa and a dopamine
agonist. Three patients in the PD-RBD group did not use
medication, three were on levodopa monotherapy, four on
dopamine agonist monotherapy, and twelve used a com-
bination of levodopa and a dopamine agonist. Use of anti-
depressants was not different between groups.
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Sleep parameters
Objective sleep quality in PD + RBD patients was lower;
patients with RBD spent more time awake, and had a
shorter total sleep time and lower sleep efficiency (Table 3).
The prevalence of sleep disorders other than RBD was not
different between groups (Table 3).
Actigraphy
Actigraphy results are presented in Table 4, both during
the first night (i.e. simultaneous with the video-PSG)
and for the eight consecutive nights in total. In contrast
to the PSG results, total sleep time and sleep efficiency
as estimated by actigraphy were not different between
patients with and without PD, both during the first night
and overall eight nights. The total number of bouts clas-
sified as wake was 30% higher in the PD + RBD compared
to PD-RBD group (PD + RBD 73.2 ± 40.2 vs. PD-RBD
48.4 ± 23.3, p = .016). This was not the case for the
length of the wake bouts. Total activity and mean activity
scores during sleep were not different either. As several
clinical characteristics differed between patients with and
without PD, comparisons were repeated using multiple
regression analyses corrected for these variables, however
this did not change the results. Although a correlation
was found between number of bouts classified as wake
and actual wake time (r = .31, p = .039), regression analysis
Table 2 Clinical and disease characteristics
RBD+ RBD- p
N 23 22
Men (%) 17 (73.9) 13 (59.1) .292
Age (yr) 64.3 ± 9.4 58.1 ± 8.8 .028
Disease characteristics
Disease duration (yr) 9.5 ± 6.4 4.3 ± 2.8 .024
LED (mg/day) 1089.4 ± 582.9 697.7 ± 563.1 .027
LED night (mg/day) 117.2 ± 51.8 140.6 ± 40.9 .298
Hoehn & Yahr (%) .025
1 - 2 (9.1)
1.5 - 4 (18.2)
2 16 (69.6) 13 (59.1)
2.5 4 (17.4) -
3 3 (13.0) 3 (13.6)
Use of anti-depressants
SSRI (%) 4 (17.4) 4 (18.2) .945
TCA (%) - 2 (9.1) .139
Other (%) 3 (13.0) - .080
Results are mean ± SD, except if otherwise specified.
LED, Levodopa equivalent dose.
LED night Levodopa Equivalent Dose taken before going to bed.
SSRI, selective serotonin reuptake inhibitors.
TCA, tricyclic antidepressants.
Bold p values are significant.




Total sleep time (min) 330.0 ± 51.6 375.6 ± 65.9 .008
Sleep efficiency (%) 67.9 ± 8.7 76.3 ± 10.7 .004
Sleep latency (min) 13.8 ± 12.2 10.1 ± 8.1 .138
% N1 15.2 ± 8.0 10.3 ± 5.2 .037
% N2 58.9 ± 11.3 58.0 ± 10.9 .677
% N3 13.0 ± 11.3 15.7 ± 9.5 .304
% REM 13.0 ± 8.3 15.9 ± 7.2 .118
% Wake 30.0 ± 9.4 22.6 ± 10.9 .003
Awakenings (no.) 35.3 ± 14.5 28.9 ± 11.1 .109
PLM index 36.2 ± 47.2 21.7 ± 31.9 .138
Other sleep diagnoses
Insomnia (%) 18 (78.3) 18 (81.8) .766
OSAS (%) 6 (26.1) 9 (40.9) .292
RLS (%) 6 (26.1) 6 (27.3) .928
Hypersomnia (%) 12 (52.2) 8 (36.4) .286
Results are mean ± SD, except if otherwise specified.
% N1(N2, N3, REM) = percentage in stage N1 (N2, N3, REM) sleep), PLM, periodic
limb movement; OSAS, obstructive sleep apnea syndrome; RLS, restless
legs syndrome.
Bold p values are significant.




Total sleep time (min) 396.5 ± 72.0 429.1 ± 58.4 .103
Sleep efficiency 82.7 ± 12.3 87.6 ± 8.7 .133
Sleep latency (min) 3.3 ± 6.5 2.4 ± 4.7 .580
No wake bouts 78.4 ± 46.1 49.5 ± 22.2 .011
Length wake bouts (min) 1.1 ± 0.5 1.2 ± 0.6 .488
Total activity score 12943.8 ± 11432.2 10132.6 ± 6847.6 .325
Mean activity score 6.9 ± 5.7 5.4 ± 3.9 .299
Actigraphy mean of 8 nights
Total sleep time (min) 397.4 ± 91.1 389.5 ± 64.1 .738
Sleep efficiency 78.4 ± 14.6 84.7 ± 9.5 .097
Sleep latency (min) 10.0 ± 10.6 5.8 ± 10.3 .187
No wake bouts 73.2 ± 40.2 48.4 ± 23.3 .016
Length wake bouts (min) 1.3 ± 0.6 1.4 ± 0.5 .689
Total activity score 17885.2 ± 14375.8 12613.9 ± 9793.2 .160
Mean activity score 10.4 ± 11.5 7.2 ± 5.4 .231
Results are mean ± SD, except if otherwise specified.
% N1(N2, N3, REM) = percentage in stage N1 (N2, N3, REM) sleep), PLM,
periodic limb movement; OSAS, obstructive sleep apnea syndrome, RLS,
restless legs syndrome.
Bold p values are significant.
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correcting for actual wake time still showed a significant
effect of the presence of RBD on the number of wake bouts
(R-squared = 0.18, standardized-beta = 0.31, p = .043).
Actigraphy in clinical practice
To study the clinical relevance of the previous findings,
we calculated the sensitivity, specificity and the positive
and negative predictive value of actigraphy for the diag-
nosis of RBD. Figure 1 shows the distribution of wake
bouts in the PD + RBD and PD-RBD groups. A cut-off
of 95 wake bouts per night yielded a specificity of 95.5%,
a sensitivity of 26.1%, a positive predictive value of 85.7%
and a negative predictive value of 55.3%. Figure 2 shows
the ROC curve when using different cut-offs for the
number of wake bouts during the eight measurement
nights. The area under the curve was 0.696 with a sig-
nificance of p = .025. Figure 3 shows the resulting posi-
tive and negative predictive values according to different
prevalence rates of RBD; which in our cohort was 51.1%.
We additionally looked at the final diagnosis for pa-
tients where the clinical interview was incongruent with
the final diagnosis of RBD. Based on the clinical inter-
view, seven patients were suspected of having RBD, but
did not fulfill the full ICSD-II criteria. All but one of
these patients had sleep initiation or maintenance prob-
lems (insomnia); two were diagnosed with obstructive
sleep apnea syndrome, two had restless legs syndrome,
three showed an increased level of periodic leg move-
ments, and one suffered from nocturnal hallucinations
(Table 5). Six of the patients had a wake bout count lower
95 (Table 5). Seven patients did not have a clinical history
of RBD, but PSG findings allowed an RBD diagnosis ac-
cording to the ICSD-II criteria. In these patients there
was either no bed partner, or the bed partner claimed to
be always fast asleep not noticing any abnormal behavior
of the patient. Additional sleep diagnoses in this group
are listed in Table 5. The actigraphy-based number of
wake bouts in this group was highly diverse, showing no
consistent direction.
Discussion
Solely using the clinical interview to assess the possible
presence of RBD in PD patients, often results in mis-
diagnoses. However, even judicious use of video-PSG is
costly and not always feasible. Therefore, there is a clear
need for new screening tools for RBD. Our results show
that using actigraphy, the number of bouts classified
as “wake” is significantly higher in PD patient with
RBD compared to PD patients without. Accordingly,
we show that actigraphy has a very high specificity and
a good positive predictive value for diagnosing RBD in
PD patients.
Wake bouts as scored by actigraphy were previously
suggested as a possible useful marker in the diagnostic
workup of RBD in PD: our findings are in agreement
with Naismith et al., who studied 22 patients with 14
consecutive nights of actigraphy [15]. However, the ac-
tual number of wake bouts was almost twice as high in
our patient group, compared to theirs. Since sensitivity
settings of the actigraphs were the same, this difference
may have been caused by different epoch length settings,
which was 0.25 min in our study and 0.50 in the study
Figure 1 Distribution of wake bouts across groups. Boxplot of number of wake bouts per night measured over 8 nights in PD with without
and with RBD.
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of Naismith et al. [15]. In addition, we used video-PSG in
combination with a clinical interview by a sleep medicine
specialist as the gold standard for the diagnosis of RBD,
instead of questionnaires.
Previous studies have suggested that actigraphy is an
useful method to measure sleep quality in PD patients.
Correlations were found between actigraphy and total sleep
time, wake after sleep onset and subjective complaints
about nocturnal sleep [13,14]. Our results however showed
a difference between total sleep time and sleep efficiency
measured with actigraphy and PSG. Although the acti-
graph was measured on the least affect side, we cannot ex-
clude that the presence of tremor, on-off fluctuations and/
or dyskinesias may have influenced the results. More re-
search is needed to study the influence of PD motors
symptoms on actigraphic results during the night.
Figure 2 ROC curve using number of wake bouts in diagnosis of RBD. Area under the curve (AUC) = 0.696.
Figure 3 Predictive value of actigraphy for RBD in PD, in relation to RBD prevalence.
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There was no increase in either total or mean activity
levels during sleep, which could have been expected in
patients with REM related movements. However, as RBD
associated movements lead to activity well above the
threshold that is represented as “sleep” by actigraphy, they
are almost always scored as “wake bouts” rather than in-
creased activity during sleep. Variables other than the pres-
ence of RBD may have influenced the number of bouts
classified as wake. The periodic limb movement index was,
although not significantly, higher in the PD + RBD group
compared to the PD-RBD group. The lack of significance
could be caused by a large difference in variance. Periodic
limb movements can cause sleep disturbances and there-
fore increase the number of wake bouts. Our groups were
not matched with respect to age, disease duration, disease
stage and medication use, and these factors may also influ-
ence sleep. However, regression analyses correcting for
these clinical characteristics and PSG-determined actual
wake time during the night, still showed a significant differ-
ences in the number of wake bouts between groups. These
findings suggest that the increased number of wake bouts
is primarily the result of the presence of RBD.
Results showed that using an epoch length of 0.25 min
and a cut-off of 95 wake bouts per night, actigraphy is a
highly specific tool for RBD in PD patients, albeit with a
low sensitivity. As the prevalence of RBD in PD ranges
between 30% and 60% [1-3], actigraphy has a positive
predictive value between 70 and 90% which is reason-
able. Based on a semi-structured clinical interview alone,
we found seven patients incorrectly suspected of having
RBD. Of these, only one patient scored above the thresh-
old of 95 wake bouts per night. Therefore, these results
show an additional value of using actigraphy next to a
clinical interview in the diagnostic trajectory of RBD.
Seven patients had no clinical history of RBD-like behav-
ior but still fulfilled the diagnostic PSG criteria of RBD,
and actigraphy did not differentiate these patients from
the group without RBD. Actigraphy therefore mainly has
a role in combination with at least a clinical suspicion of
RBD, rather than a screening instrument in PD patients
without complaints of RBD. Actigraphy should not be
used in the diagnosis of idiopathic RBD: although clear
studies about the prevalence of RBD in the general eld-
erly population are lacking, rates are estimated between
0.38% and 0.50%, leading to a positive predictive value
below 5% [19,20].
Contrary to the high specificity and low sensitivity of
actigraphy, previous research showed that RBD ques-
tionnaires have a high sensitivity and a somewhat low
specificity [8,10-12]. Combining actigraphy and RBD ques-
tionnaires could therefore lead to a more accurate diagno-
sis of RBD. The combination of these two tools could
reduce the need for video-PSG even more. Future research
should focus on the clinical value of using a combination
of both methods.
Our study used the ICSD-II criteria for the diagnosis
of RBD. These criteria are not unambiguous unfortu-
nately. They include presence of atonia during REM
sleep, which represents a pathological increase of either
phasic EMG activity, tonic EMG activity or both. Cut-off
points to diagnose pathological increased phasic and tonic
EMG activity are not mentioned in the criteria however,
and no agreement has been reached on this point among
international research groups. Here, we therefore adopted
the criteria developed by the SinBar group, although sev-
eral other visual and computerized scoring methods have
been mentioned in literature [2,18,21-26].
Conclusions
PD patients with RBD showed a significantly higher
number of bouts scored as “wake” using actigraphy, com-
pared to patients without RBD. In clinical practice, acti-
graphy has a high specificity, but low sensitivity in the
diagnosis of RBD. According to our results and previous
studies on the use of RBD questionnaires, the combination
of both tools could be a promising method to diagnose
RBD in PD patients, leading to a decrease in the need for
the costly and time-consuming video-PSG.
Table 5 Mismatch between RBD diagnosis based on
clinical interview and ICSD II criteria
PD patients with clinical interview suspicious for RBD but not
confirmed by ICSD II criteria
Study
number
Final diagnoses Number of wake bouts
according to actigraphy
21 OSAS 52.4
24 Insomnia, PLMD 100.7
29 Insomnia, PLMD, hallucinations 19.4
32 Insomnia, RLS 56.3
48 Insomnia 28.0
71 Insomnia, RLS, PLMD 83.5
73 Insomnia, OSAS 42.1
PD patients with clinical interview negative for RBD but with
diagnosis based on ICSD II criteria
Study
number
Other diagnoses next to RBD Number of wake bouts
according to actigraphy
1 Insomnia, OSAS, RLS 108.1
12 Insomnia, RLS, PLMD 92.3
16 Insomnia 59.8
44 Insomnia 25.7
45 Insomnia, RLS, PLMD 189.3
65 Insomnia, RLS 32.9
75 Insomnia, PLMD 71.5
OSAS, obstructive sleep apnea syndrome, PLMD, periodic leg movement
disorder, RLS, restless legs syndrome.
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